Editor’s Note: a Brief History of Preventative Antimigraine Therapy (PAMT)

  • James R. CouchEmail author
Headache (JR Couch, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Headache

The idea of PAMT has been a concept sought by physicians treating headache and migraine since antiquity and has spawned a number of unique approaches ranging from trepanation in ancient societies to implanting garlic pods under the skin of the forehead as described in the tenth century by abou l’ouasim, to feverfew and application of poultices of millipedes and woodlice by Thomas Willis in the seventeenth century [1]. In the modern era, PAMT begins with methysergide and the work done by Sicuteri [2], Friedman, Graham, and others beginning in the 1950s. Methysergide was found to have a preventative antimigraine effect but was also found to have many acute and subacute side effects as well as the longer term complications of retroperitoneal, pleuropulmonary, and cardiac fibrosis. These complications limited the use of methysergide as other PAMT agents were identified [3].

In the late 1960s and 1970s, work by Lance and his group began to test other agents of antihistamine and...


Compliance with Ethical Standards

Conflict of Interest

Dr. James Couch is currently serving as section editor for the Headache section of the Current Treatment Options in Neurology journal.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

  1. 1.
    Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. 2nd ed. London: Martin Dunitz, Ltd; 2002. p. p1–8.Google Scholar
  2. 2.
    Sicuteri F. Prophylactic and therapeutic properties of l-methyl-lysergic acid butalnoamide in migraine. Int Arch Allergy. 1959;15:78–93.Google Scholar
  3. 3.
    Silberstein SD. Methysergide. Cephalalgia. 1998;18:421–35.CrossRefGoogle Scholar
  4. 4.
    Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695–9.CrossRefGoogle Scholar
  5. 5.
    Ekbom K, Lundberg PO. Clinical trial of LB-46 (d,1-4 (2-hydroxy-3-isopropylaminopropoxy) )indol, an adrenergic beta-receptor blocking agent in migraine prophylaxis. Headache. 1972;12:15–7.CrossRefGoogle Scholar
  6. 6.
    Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology. 1972;22:366–9.CrossRefGoogle Scholar
  7. 7.
    International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia. 1988;8(Suppl. 7):1–96.Google Scholar
  8. 8.
    Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache. Analysis of factors. Headache. 1982;22:66–8.CrossRefGoogle Scholar
  9. 9.
    Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871–5.CrossRefGoogle Scholar
  10. 10.
    Couch JR. Update in chronic daily headache. Curr Treat Options Neurol. 2011;13:41–55.CrossRefGoogle Scholar
  11. 11.
    Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.CrossRefGoogle Scholar
  12. 12.
    Lenaerts ME, Couch JR. Medication overuse headache. Minerva Med. 2007;98:221–31.PubMedGoogle Scholar
  13. 13.
    Mathew NT, Saper JR, Silberstein SD. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281–6.CrossRefGoogle Scholar
  14. 14.
    Brandes JL, Saper JR, Diamond M, Couch FR, Lewis DW, Schmitt J, et al. For the MIGR-002 study group. Topiramate for migraine prevention a randomized controlled trial. JAMA. 2004;291(8):965–73.CrossRefGoogle Scholar
  15. 15.
    Diener HC, Tfelt-Hansen P, Dahlof C. Topiramate in migraine prophylaxis. J Neurol. 2004;250:943–50.Google Scholar
  16. 16.
    Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Aurora SK, et al. PREEMPT 1 chronic migraine study group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.CrossRefGoogle Scholar
  17. 17.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.University of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations